Recombinant non-collagenous domain of α2(IV) collagen causes involution of choroidal neovascularization by inducing apoptosis

Journal of Cellular Physiology

Volumn 208, Issue 1, 2006, Pages 161-166

  Lima E Silva, Raquel ^a   Kachi, Shu ^a   Akiyama, Hideo ^a   Shen, Jikui ^a   Aslam, Sadia ^a   Gong, Yuan Yuan ^a   Khu, Naw Htee ^a   Hatara, Maria C ^a   Boutaud, Ariel ^b   Peterson, Robert ^b   Campochiaro, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BioStratum Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CANSTATIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BASEMENT MEMBRANE; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RETINA MACULA AGE RELATED DEGENERATION; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CHOROID; CHOROIDAL NEOVASCULARIZATION; COLLAGEN TYPE IV; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; FEMALE; IN SITU NICK-END LABELING; INJECTIONS; LASERS; MACULAR DEGENERATION; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS;

EID: 33744944283     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20645     Document Type: Article

References (41)

1. Auricchio A, Behling KC, Maguire AM, O'Conner EM, Bennett J, Wilson JM, Tolentino MJ. 2002. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther 6:490-494.
2. Brooks P, Clark R, Cheresh D. 1994. Requirement of vascular integrin alpha-v beta-3 for angiogenesis. Science 264:569-571.
3. Collo G, Pepper MS. 1999. Endothelial cell integrin alpha5beta1 expression is modulated by cytokines and during migration in vitro. J Cell Sci 112:569-578.
4. Colorado PC, Torre A, Kamphaus G, Maeshima Y, Hopfer H, Takahashi K, Volk R, Zamborsky ED, Herman S, Sarkar PK, Erickson MB, Dhanabal M, Simons M, Post M, Kufe DW, Weichselbaum RR, Sukhatme VP, Kalluri R. 2000. Anti-angiogenic cues from vascular basement membrane collagen. Canc Res 60:2520-2526.
5. Egeblad BP, Werb Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174.
6. Fleischmajer R, Kuhn K, Sato Y, MacDonald EDn, Perlish JS, Pan TC, Chu ML, Kishiro Y, Oohashi T, Bernier SM, Yamada Y, Ninomiya Y. 1997. There is temporal and spatial expression of alpha1(IV), alpha2(IV), alpha5(IV), and alpha6(IV) collagen chains and beta 1 integrins during the development of the basal lamina in an "in vitro" skin model. J Invest Dermatol 109:527-533.
7. Forin DM, Pratt BM, Madri JA. 1986. Endothelial cell proliferation during angiogenesis. In vitro modulation by basement membrane components. Lab Invest 55:521-530.
8. Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Duh EJ, Yang HS, Cingolani C, Lai H, Wei L, Campochiaro PA. 2003a. Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. Gene Ther 10:637-646.
9. Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Xiao WH, Duh EJ, Yang HS, Lai H, Kovesdi I, Wei L, Campochiaro PA. 2003b. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and VEGF-induced breakdown of the blood-retinal barrier. Hum Gene Ther 14:129-141.
10. Gragoudas ES, Adamis AP, Cunningham ET, Jr., Feinsod M, Guyer DR. 2004. Pegaptanib for neovascular age-related macular degeneration. N Eng J Med 351:2805-2816.
11. Hudson BG, Reeders ST, Tryggvason K. 1993. Type IV collagen: Structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport sydromes and diffuse leiomyomatosis. J Biol Chem 268:26033-26036.
12. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torres A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri R. 2000. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 275:1209-1215.
13. Kim S, Bell K, Mousa SA, Varner JA. 2000. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 156:1345-1362.
14. Kwak N, Okamoto N, Wood JM, Campochiaro PA. 2000. VEGF is an important stimulator in a model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41:3158-3164.
15. Lai C-C, Wu W-C, Chen S-L, Xiao X, Tsai T-C, Huan S-J, Chen T-L, Tsai RJ-F, Tsao Y-P. 2001. Suppression of choroidal neovascularization by adenoassociated virus vector expressing angiostatin. Invest Ophthalmol Vis Sci 42:2401-2407.
16. Luna J, Tobe T, Mousa SA, Reilly TM, Campochiaro PA. 1996. Antagonists of integrin alpha-v beta-3 inhibit retinal neovascularization in a murine model. Lab Invest 75:563-573.
17. Madri J, Reidy M, Kocher O, Bell L. 1989. Endothelial cell behavior following denudation injury is modulated by TGF-beta and fibronectin. Lab Invest 60:755-765.
18. 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 275:23745-23750.
19. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grankemeyer JA, Ericksen MB, Hopfer H, Xiao Y, Stillman IE, Kalluri R. 2000b. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 275:21340-21348.
20. Magnussen A, Kasman IM, Norberg S, Baluk P, Murray R, McDonald DM. 2005. Rapid access of antibodies to alpha5beta1 integrin overexpressed on the luminal surface of tumor blood vessels. Cancer Res 65:2712-2721.
21. Miner JH, Sanes JR. 1994. Collagen IV alpha 3, alpha 4, and alpha 5 chains in rodent basal laminae: Sequence, distribution, association with laminins, and developmental switches. J Cell Biol 127:879-891.
22. Mori K, Ando A, Gehlbach P, Nesbitt D, Takahashi K, Goldsteen D, Penn M, Chen CT, Melia M, Phipps S, Moffat D, Brazzell K, Liau G, Dixon KH, Campochiaro PA. 2001a. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 159:313-320.
23. Mori K, Duh E, Gehlbach P, Ando A, Takahashi K, Pearhnan J, Mori K, Yang HS, Zack DJ, Ettyreddy D, Brough DE, Wei LL, Campochiaro PA. 2001b. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 188:253-263.
24. Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA. 2001c. Regression of ocular neovascularization by increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 43:2428-2434.
25. Mori K, Gehlbach P, Yamamoto S, Duh E, Zack DJ, Li Q, Berns KI, Raisler BJ, Hauswirth WW, Campochiaro PA. 2002. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 43:1994-2000.
26. Nguyen QD, Shah SM, Tatlipinar S, Do DV, Van Anden E, Campochiaro PA. 2005. Bevacizumab suppresses choroidal neovascularization due to pathologic myopia. Br J Ophthalmol 89:1368-1370.
27. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birknead JR, Olsen BR, Folkman J. 1997. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285.
28. Oberbaumer I, Wiedemann H, Timpl R, Kuhn K. 1982. Shape and assembly of type IV procollagen obtained from cell culture. EMBO J 1:805-810.
29. Ortega N, Werb Z. 2002. New functional roles for noncollagenous domains of basement membrane collagens. J Cell Sci 115:4201-4214.
30. Parsons-Wingerter P, Kasman IM, Norberg S, Magnussen A, Zanivan S, Rissone A, Baluk P, Favre CJ, Jeffry U, Murray R, McDonald DM. 2005. Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors. Am J Pathol 167:193-211.
31. Petitclerc C, Boutaud A, Prestayko A, Xu J, Sado Y, Ninomiya Y, Sarras MP, Jr., Hudson BG, Brooks PC. 2000. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 275:8051-8061.
32. Ramchandran R, Dhanabal M, Volk R, Waterman MJ, Segal M, Lu H, Knebelmann B, Sukhatme VP. 1999. Antiangiogenic activity of restin, NC10 domain of human collagen XV: Comparison to endostatin. Biochem Biophys Res Comm 255:735-739.
33. R1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195:241-248.
34. Shahan T, Grant D, Tootell M, Ziaie Z, Ohno N, Mousa SA, Mohamad S, DeLisser HM, Kefalides N. 2004. Oncothanin, a peptide from the alpha 3 chain of type IV collagen, modifies endothelial cell function and inhibits angiogenesis. Connect Tissue Res 45:151-163.
35. Shen GQ, Butkowski R, Cheng T, Wieslander J, Katz A, Cass J, Fish AJ. 1990. Comparison of non-collagenous type IV collagen subunits in human glomerular basement membrane, alveolar basement membrane, and placenta. Connect Tissue Res 24:289-301.
36. Sundaramoorty M, Meiyappan M, Todd P, Hudson BG. 2002. Crystal structure of NC1 domains. Structural basis for type IV collagen assembly in basement membranes. J Biol Chem 277:31142-31153.
37. Takahashi T, Nakamura T, Hayashi A, Kamei M, Nakabayashi M, Okada AA, Tomita N, Daneda Y, Tano Y. 2000. Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium. Amer J Ophthalmol 130:774-781.
38. Takahashi K, Saishin Y, Saishin Y, Lima Silva R, Oshima Y, Oshima S, Melia M, Paszkiet B, Zerby D, Kadan MJ, Liau G, Kaleko M, Connelly S, Luo T, Campochiaro PA. 2003. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J 17:896-898. Epub 2003 Mar 28.
39. Tanaka K, Iyama K, Kitaoka M, Ninomiya Y, Oohashi T, Sado Y, Ono T. 1997. Differential expression of alpha 1(IV), alpha 2 (IV), alpha 5(IV), and alpha 6 (IV) collagen chains in the basement membrane of basal cell carcinoma. Histochem J 29:563-570.
40. Tobe T, Ortega S, Luna JD, Ozaki H, Okamoto N, Derevjanik NL, Vinores SA, Basilico C, Campochiaro PA. 1998. Targeted disruption of theFGF2gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 153:1641-1646.
41. Xu J, Rodriguez D, Petitclerc C, Kim JJ, Hangai M, Moon SM, Davis GE, Brooks PC. 2001. Proteolytic exposure of a cryptic site within collagen type-IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154:1069-1079.